Bio B2B 〉 Selective Search Results
Your Selection Setting ：Respiratory System；
Selective Search Results :
Pipeline & Platform 4 record(s)；
low-alcohol formulation (iLEF) platform
Intech Biopharm focus on new dosage, new combination, new delivery and high barrier generic drug development and manufacturing for respiratory therapy area. We are currently one of the leading companies, and the only one in Taiwan, that can provide and manufacture high barrier obstructive airway diseases drug and our competitive advantage are as follow: iLEF platform: It has a low-alcohol
FB825 is a humanized monoclonal antibody that binds to the CεmX domain, leading to death of the membrane IgE+ B lymphocytes by inducing apoptosis and antibody-dependent cellular cytotoxicity (ADCC) in a dosing-dependent manner. FB825 can stand alone as a monotherapy or in combination with Xolair for the treatment of allergic asthma and IgE-mediated diseases.
Multiple-Phasic Release Technology (MPRT)
Through Orient Pharma's patented technology, incompatible ingredients or drugs with different release profiles can be enclosed in a single capsule or tablet for the development of new drugs.
AmCAD-UO is an innovative solution to assist physicians evaluating the risk of Obstructive Sleep Apnea (OSA) syndrome.The solution consists of a positioning system and a computer-assisted detection software device.The evaluation process is performed on awake patients and takes no more than 10 minutes to get the results.The entire process is objective, accurate, cost-effective and safe and is expected